Various radiolabeled benzamide analogues have been developed for targeting melanin with high selectivity and affinity [ 15– 15].
However, the available JNK inhibitors have not been developed for rheumatic diseases yet and could have issues related to potency and selectivity.
Phlorizin has not been developed for clinical use for several reasons, including metabolic instability, low oral bioavailability, and a lack of selectivity for SGLT2.
Additionally, a consistency test is developed for analyzing the selectivity coefficient plots.
A regression model was developed for the pervaporation flux and selectivity as a function of the operating conditions: temperature, concentration and flow-rate.
Therefore, novel TK inhibitors with improved selectivity are being developed for the treatment of diseases associated with KIT activation.
A new analytical method was developed for 1,3-butadiene that increased the sensitivity and selectivity of the previous NIOSH method.
Cyclic sulfates have been developed that show selectivity for cathepsin B over calpain, presumably due to the steric hindrance in the calpain active site 81, 82.
However, to date no potent small molecule inhibitors have been developed with selectivity towards MRCK.
However, several chemical classes of 5-HT4 receptor agonists have been developed, and the selectivity of different compounds for the 5-HT4 receptoverver other targets is highly variable between individual drugs and drug classes.
